| Primary |
| Product Used For Unknown Indication |
47.3% |
| Staphylococcal Infection |
6.7% |
| Drug Use For Unknown Indication |
5.9% |
| Endocarditis |
5.2% |
| Staphylococcal Bacteraemia |
4.8% |
| Off Label Use |
4.6% |
| Osteomyelitis |
4.2% |
| Enterococcal Infection |
2.4% |
| Device Related Infection |
2.2% |
| Enterococcal Bacteraemia |
2.1% |
| Endocarditis Staphylococcal |
2.1% |
| Bacteraemia |
2.0% |
| Sepsis |
2.0% |
| Cellulitis |
1.9% |
| Infection |
1.8% |
| Staphylococcal Sepsis |
1.1% |
| Skin Infection |
1.0% |
| Hypertension |
1.0% |
| Prophylaxis |
0.8% |
| Arthritis Bacterial |
0.8% |
|
| Death |
18.9% |
| Eosinophilic Pneumonia |
10.3% |
| Blood Creatine Phosphokinase Increased |
9.3% |
| Rhabdomyolysis |
9.1% |
| Septic Shock |
5.0% |
| International Normalised Ratio Increased |
4.3% |
| Staphylococcal Bacteraemia |
4.1% |
| Renal Failure Acute |
4.1% |
| Sepsis |
4.0% |
| Thrombocytopenia |
3.6% |
| Pneumonia |
3.5% |
| Renal Failure |
3.4% |
| Treatment Failure |
3.4% |
| Pyrexia |
2.8% |
| Endocarditis |
2.6% |
| Rash |
2.6% |
| Infection |
2.5% |
| Staphylococcal Infection |
2.3% |
| Respiratory Failure |
2.2% |
| Drug Ineffective |
2.1% |
|
| Secondary |
| Product Used For Unknown Indication |
45.0% |
| Drug Use For Unknown Indication |
7.6% |
| Off Label Use |
6.9% |
| Staphylococcal Infection |
5.3% |
| Staphylococcal Bacteraemia |
5.1% |
| Endocarditis |
5.1% |
| Osteomyelitis |
4.2% |
| Device Related Infection |
3.0% |
| Enterococcal Infection |
2.7% |
| Sepsis |
2.0% |
| Streptococcal Bacteraemia |
1.7% |
| Arthritis Infective |
1.7% |
| Cellulitis |
1.7% |
| Bacteraemia |
1.6% |
| Endocarditis Staphylococcal |
1.5% |
| Enterococcal Bacteraemia |
1.1% |
| Infection |
1.1% |
| Staphylococcal Sepsis |
1.0% |
| Antibiotic Therapy |
1.0% |
| Skin Infection |
0.9% |
|
| Death |
11.7% |
| Septic Shock |
8.7% |
| Sepsis |
8.5% |
| Staphylococcal Bacteraemia |
7.2% |
| Blood Creatine Phosphokinase Increased |
7.1% |
| Renal Failure Acute |
6.4% |
| Treatment Failure |
5.5% |
| Rhabdomyolysis |
4.9% |
| Drug Ineffective |
4.6% |
| Drug Ineffective For Unapproved Indication |
3.9% |
| Eosinophilic Pneumonia |
3.7% |
| Neuropathy Peripheral |
3.7% |
| Pneumonia |
3.5% |
| Thrombocytopenia |
3.4% |
| Renal Failure |
3.2% |
| Enterococcal Bacteraemia |
3.0% |
| Endocarditis |
2.8% |
| Multi-organ Failure |
2.8% |
| Pyrexia |
2.8% |
| Infection |
2.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
39.4% |
| Pain |
7.4% |
| Multiple Myeloma |
6.5% |
| Pyrexia |
4.6% |
| Crohn's Disease |
4.1% |
| Nausea |
4.1% |
| Prophylaxis |
3.9% |
| Anxiety |
3.3% |
| Osteomyelitis |
3.3% |
| Constipation |
3.1% |
| Anaphylaxis Prophylaxis |
3.0% |
| Vomiting |
3.0% |
| Infection Prophylaxis |
2.2% |
| Gastrooesophageal Reflux Disease |
1.9% |
| Hypersensitivity |
1.9% |
| Metastases To Bone |
1.9% |
| Chronic Hepatitis C |
1.7% |
| Prophylaxis Against Graft Versus Host Disease |
1.7% |
| Staphylococcal Infection |
1.7% |
| Acute Myeloid Leukaemia |
1.5% |
|
| Sepsis |
13.5% |
| Pericarditis |
7.7% |
| Blood Creatinine Increased |
5.8% |
| Death |
5.8% |
| Staphylococcal Infection |
5.8% |
| Subarachnoid Haemorrhage |
5.8% |
| Thrombocytopenia |
5.8% |
| Wound Infection |
5.8% |
| Acute Respiratory Distress Syndrome |
3.8% |
| Joint Swelling |
3.8% |
| Off Label Use |
3.8% |
| Pulmonary Embolism |
3.8% |
| Pyrexia |
3.8% |
| Rash |
3.8% |
| Renal Failure Acute |
3.8% |
| Staphylococcal Sepsis |
3.8% |
| Tongue Oedema |
3.8% |
| Urine Colour Abnormal |
3.8% |
| Vision Blurred |
3.8% |
| Acute Graft Versus Host Disease In Liver |
1.9% |
|
| Interacting |
| Product Used For Unknown Indication |
59.4% |
| Acute Promyelocytic Leukaemia |
15.6% |
| Hepatitis C |
9.4% |
| Hiv Infection |
6.3% |
| Sepsis |
6.3% |
| Staphylococcal Infection |
3.1% |
|
| Drug Interaction |
55.6% |
| Lactic Acidosis |
11.1% |
| Myositis |
11.1% |
| Renal Failure Acute |
11.1% |
| Rhabdomyolysis |
11.1% |
|
